

Konwave ATG Emerging Markets Healthcare

Factsheet September 2026 - as of 30.09.2026

This document is a marketing communication



FUND DESCRIPTION

Investment Objective:

The Fund aims to achieve attractive long-term capital appreciation and seeks to outperform its benchmark over rolling three- and five-year periods. It targets an annual outperformance of 2% to 3% after fees.

Philosophy:

The Fund follows a disciplined bottom-up investment approach based on the proven GARP philosophy (Growth at a Reasonable Price), combining the opportunities of high-growth companies with attractive valuations. Investments are selectively made in listed small-, mid-, and large-cap companies in the healthcare sector across Emerging Markets. ESG criteria are firmly embedded in the investment process and support responsible and sustainable security selection.

Investment Strategy:


To achieve its investment objective, the Fund invests at least 80% of its net asset value in equities of healthcare companies from Emerging Markets. The focus is on promising companies in the pharmaceutical, biotechnology, medical technology, and healthcare services sectors, as well as related areas such as diagnostics, digital health companies, and contract manufacturers. The portfolio is constructed with a focused approach and typically comprises 30 to 50 carefully selected individual positions.

MONTHLY PERFORMANCE


USD -F-	Dec 25*	Jan 26	Feb 26	Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	Sep 26	YTD
Konwave ATG EM HC	-3,66%	3,56%	0,08%	-8,80%	3,59%	-4,26%	-1,53%	4,49%	7,16%	0,03%	3,38%
MSCI EM HC	-4,51%	3,16%	2,89%	-9,96%	3,98%	-2,89%	0,10%	5,12%	8,68%	-0,58%	9,71%

* Inception
4/12/2025

COUNTRY ALLOCATION



SECTOR ALLOCATION



Konwave ATG Emerging Markets Healthcare

Factsheet September 2026 - as of 30.09.2026

This document is a marketing communication



FUND DATA

NAV / ISIN / Sedol USD F ACC	USD 99,60 / IE000500SX60 / BW2FJY3	Type	Open end
ISIN USD I ACC	IE000TFAVGX2	Domicile	Ireland
ISIN CHF I ACC	IE00006NU398	SFDR Classification	Article 8
ISIN EUR I ACC	IE000L47KBG2	Custodian	Northern Trust International Fund Administration
ISIN CHF Q ACC	IE000LKCWQ93		
		Fund Mgmt	
		Company	Harrington Cooper UCITS Funds ICAV
		Investment	
		Manager	ATG Healthcare Investments AG
		Auditor	Deloitte Ireland
			0,6%-0,8%* p.a. (F)
		Management fee	0,9% p.a. (I) / 1,5% p.a. (Q)
		Adm. / Custody fee	ca. 0,2%** p.a.
		Pricing / Cut-Off	Daily / 12:00 Noon (Ireland)
		Issue fee	0%
		Redemption fee	0%

* Depending on Fund Size

** Estimate

TOP-TEN HOLDINGS

COMPANY	COUNTRY	WEIGHT
Wuxi Biologics	China	9,9%
Sichuan Kelun Biotech	China	7,1%
Innovent	China	6,7%
Celltrion	South Korea	6,4%
BeOne	China	5,3%
Wuxi Apptec	China	4,9%
Hansoh Pharmaceutical	China	4,2%
Sun Pharmaceuticals	India	4,1%
Wuxi XDC	China	3,3%
Mindray	China	3,0%

Total Top 10 54,9%

COUNTRY ALLOCATION

China	59,0%
India	15,8%
South Korea	11,5%
Brazil	2,4%
Others	10,1%
Cash	1,2%

STATISTICAL DATA (USD -F-)

Annualised return	n.a.
Return since inception	-0,40%
Inception date	4.12.2025
Volatility	n.a.
Information ratio	n.a.
Tracking error	n.a.
Fund size (all share classes)	USD 52,2mn

MARKET CAPITALISATION ALLOCATION

Large Caps (>20bn USD)	53,7%
Mid Caps (5 – 20bn USD)	37,8%
Small Caps (< 5bn USD)	7,3%
Cash	1,2%

Important notes: The information on this document should be considered non-independent as Harrington Cooper LLP and Harrington Cooper Asset Management Limited have been retained by ATG Healthcare Investments AG for the promotion of the strategies and funds to professional investors in the United Kingdom and the European Union. This document does not constitute or form part of any offer to issue or sell, or any solicitation by Harrington Cooper LLP, Harrington Cooper Asset Management Limited, ATG Healthcare Investments AG or any of their affiliates, of any offer to subscribe or purchase any securities mentioned herein. The information in this document should not be construed as the making of a personal recommendation or the giving of investment advice or recommending the undertaking of any investment activity either within or outside the United Kingdom. No investment decisions should be made without first reviewing the prospectus for the Harrington Cooper UCITS Funds ICAV in conjunction with the fund supplement and the PRIIPS KID/ UCITS KIID for the share class, a summary of the investor rights and any other supplementary information, which can be obtained free of charge from <http://harringtoncooper.com/harrington-cooperasset-management-funds/>. The Prospectus and supplements for the fund are available in English. The PRIIPS KID and UCITS KIID as applicable are available in English. Where required under national rules, the key information document will also be available in the local language of the relevant EEA Member State. A decision may be taken at any time to terminate the arrangements made for the marketing of the Funds on the Harrington Cooper UCITS Funds ICAV in any EEA Member State in which it is currently marketed. In such circumstances, Shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the Fund free of any charges or deductions for at least 30 working days from the date of such notification. The value of all investments and any income derived therefrom can decrease as well as increase and capital may be lost. This information is not for use within any country or with respect to any person(s) where such use could constitute a violation of the applicable law. This document is only for professional clients or eligible counterparties (or such persons whom it may lawfully be issued or directed) In particular, any investment or services to which this document may relate are not intended for retail clients and will not be made available to retail clients. No representation, warranty or undertaking, expressed or implied, is given as to the accuracy, timeliness or completeness of the information and no liability is accepted by Harrington Cooper LLP or Harrington Cooper Asset Management Limited or ATG Healthcare Investments AG or their affiliates for the information or opinions contained in this document. Management company and distributor (European Union): Harrington Cooper Asset Management Limited, which is regulated by the Central Bank of Ireland. Registered office: Block A, One Park Place, Upper Hatch Street, Dublin 2, Ireland. Harrington Cooper UCITS Funds ICAV is authorised and regulated by the Central Bank of Ireland. Distributor (UK): Harrington Cooper LLP, which is authorised and regulated by the Financial Conduct Authority, is a Limited Liability Partnership registered in England and Wales under registration number OC319697. Registered office: The Royal Exchange, 2 Royal Exchange Steps, London, EC3V 3DG, United Kingdom. Telephone: +44 0 207 043 0500.

ATG Healthcare Investments AG
Klausstrasse 26, 8008 Zürich
Switzerland

+41 43 234 57 40
info@atg-healthcare.com
www.atg-healthcare.com